MRK ▼ -0.1% - Merck & Co., Inc. $MRK MERCK RECEIVES POSITIVE EU CHMP OPINION FOR KEYTRUDA® (PEMBROLIZUMAB) PLUS PADCEV® (ENFORTUMAB VEDOTIN-EJFV) Merck's stock slipped 0.1% today following a positive Committee for Medicinal Products for Human Use opinion recommending approval of its Keytruda and Padcev combination therapy. The favorable regulatory recommendation, which typically precedes formal EU market authorization, underscores the company's growing portfolio in oncology but had minimal impact on investor sentiment. 18-SEP-2026 06:57 AM ET